Genbank References: capsid (p24)

Authors	Title	Citation	E-value	# in Gb	#Pts	ART	Source	Cloning	StudyType
Dapp (2017)	Patterns and rates of viral evolution in HIV-1 subtype B infected females and males	PLoS ONE 12 (10), E0182443 (2017)	1.34e-169	1783	8	Naive	Plasma	SGS	Acute infection

Download sequences

Accession	IsolateName	Country	Coll Date	Clone	MolType	Source	Note	FirstAA	LastAA	MutList
MF780183	viroverse:41188.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,110S,116A,120S
MF779542	viroverse:41189.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,178T,199R,225S
MF779289	viroverse:41190.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF780404	viroverse:41191.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,15L,54L,79D,83M,148I,154K,178T,210S,225S
MF779290	viroverse:41192.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779543	viroverse:41193.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,199R,225S
MF779544	viroverse:41194.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,154K,199R,225S
MF779545	viroverse:41195.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,154K,178T,199R,225S
MF779546	viroverse:41196.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,199R,225S
MF778800	viroverse:41203.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF779201	viroverse:41204.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,110A,116A,120A,123A,148V,180D
MF778801	viroverse:41205.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,44A,83L,120H,216AT
MF779291	viroverse:41206.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779202	viroverse:41207.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF778802	viroverse:41208.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,44A,83L,120H
MF779292	viroverse:41209.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF778803	viroverse:41210.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,44A,83L,120H
MF778804	viroverse:41211.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,44A,70R,83L,120H,229GR
MF779203	viroverse:41212.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,144I,148V,180D
MF779293	viroverse:41213.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779294	viroverse:41214.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779295	viroverse:41215.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF780405	viroverse:41216.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,210S,225S
MF779296	viroverse:41217.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779297	viroverse:41218.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF780184	viroverse:41219.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,110S,116A,120S
MF779740	viroverse:41220.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6M,14P,16A,41A,83M,116A,132K,136M,141V,154K,178T,199R
MF780406	viroverse:41221.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780185	viroverse:41222.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,110S,116A,120S
MF779298	viroverse:41223.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF780186	viroverse:41224.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,110S,116A,120S
MF779547	viroverse:41225.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,154K,178T,199R,225S
MF780407	viroverse:41226.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,210S,225S
MF778805	viroverse:41933.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,44A,83L,120H
MF778806	viroverse:41934.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,44A,83L,120H
MF778807	viroverse:41937.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,44A,83L,120H
MF778808	viroverse:41940.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,44A,83L,120H
MF778809	viroverse:41942.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,14P,16A,44A,83L,95*,120H
MF779204	viroverse:41943.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779205	viroverse:41944.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779206	viroverse:41945.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779207	viroverse:41946.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,164H,180D
MF779208	viroverse:41947.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779209	viroverse:41948.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779210	viroverse:41951.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF778810	viroverse:41967.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778811	viroverse:41968.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,44A,83L,120H
MF779211	viroverse:41969.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF778812	viroverse:41973.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778813	viroverse:41974.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,44A,83L,120H
MF778814	viroverse:41975.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,44A,83L,120H
MF778815	viroverse:41976.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,44A,83L,120H
MF778816	viroverse:41989.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF779212	viroverse:41990.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF778817	viroverse:41991.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,44A,83L,120H
MF779213	viroverse:41992.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF778818	viroverse:41993.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF779214	viroverse:41994.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779215	viroverse:41995.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779216	viroverse:41996.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779217	viroverse:41997.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,17L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF778819	viroverse:41998.1	USA	Sep-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:262; viral-load:15000;CD4-count:252; CD8-count:365;subtype: B	1	231	6L,44A,83L,120H
MF779218	viroverse:41999.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF780091	viroverse:42057.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,42T,50H,91V,110N,116A,120S
MF780092	viroverse:42058.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780093	viroverse:42059.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780094	viroverse:42060.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S,155LQ
MF780095	viroverse:42061.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780096	viroverse:42062.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780097	viroverse:42063.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780098	viroverse:42064.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780099	viroverse:42065.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780100	viroverse:42066.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S,193DN
MF780101	viroverse:42067.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780102	viroverse:42068.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780103	viroverse:42069.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780104	viroverse:42070.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780105	viroverse:42071.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780106	viroverse:42072.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780107	viroverse:42073.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780108	viroverse:42074.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116T,120S
MF780109	viroverse:42075.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780110	viroverse:42076.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780111	viroverse:42077.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780112	viroverse:42078.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780113	viroverse:42079.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780114	viroverse:42080.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780115	viroverse:42081.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780116	viroverse:42082.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780117	viroverse:42083.1	USA	May-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:172; viral-load:;CD4-count:909; CD8-count:750;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF779299	viroverse:42328.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779300	viroverse:42329.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779301	viroverse:42330.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779741	viroverse:42331.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6M,14P,16A,41A,83M,116A,132K,136M,141V,154K,199R
MF779302	viroverse:42332.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779303	viroverse:42333.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L,228X
MF779742	viroverse:42334.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6M,14P,16A,41A,83M,116A,132K,136M,141V,154K,199R
MF779743	viroverse:42335.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6L,14P,16A,41A,83M,116A,132K,136M,141V,154K,199R
MF779304	viroverse:42336.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779305	viroverse:42337.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779306	viroverse:42338.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779307	viroverse:42339.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779308	viroverse:42340.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779309	viroverse:42341.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779310	viroverse:42342.1	USA	Apr-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:277; viral-load:50000;CD4-count:585; CD8-count:1536;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779744	viroverse:42343.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6L,14P,16A,41A,83M,116A,132K,136M,141V,154K,199R
MF779745	viroverse:42344.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6L,14P,16A,41A,83M,116A,132K,136M,141V,154K,199R
MF779746	viroverse:42346.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6L,14P,16A,41A,83M,116A,132K,136M,141V,154K,199R
MF779747	viroverse:42347.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6M,14P,16A,41A,83M,116A,132K,136M,141V,154K,178T,199R
MF779748	viroverse:42348.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6L,14P,16A,41A,83M,116A,132K,136M,141V,154K,199R
MF779749	viroverse:42349.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6M,14P,16A,41A,83M,116A,132K,136M,141V,154K,178T,199R
MF779750	viroverse:42350.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6L,14P,16A,41A,83M,116A,132K,136M,141V,154K,199R
MF779751	viroverse:42365.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6L,14P,16A,41A,83M,116A,132K,136M,141V,154K,199R
MF779219	viroverse:42366.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF780187	viroverse:42367.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,110S,116A,120S,231W
MF779752	viroverse:42368.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6M,14P,16A,41A,83M,116A,132K,136M,141V,154K,178T,199R
MF780188	viroverse:42369.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,110S,116A,120S
MF780189	viroverse:42370.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,110S,116A,120S
MF780190	viroverse:42371.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,110S,116A,120S
MF779753	viroverse:42373.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6M,14P,16A,41A,83M,116A,132K,136M,141V,154K,178T,199R
MF779754	viroverse:42374.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6L,14P,16A,41A,83M,116A,132K,136M,141V,154K,199R
MF779221	viroverse:42376.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779519	viroverse:42377.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779520	viroverse:42378.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779521	viroverse:42379.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779522	viroverse:42380.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779523	viroverse:42381.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779524	viroverse:42382.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779525	viroverse:42383.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779526	viroverse:42384.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,178T,199R,225S
MF779527	viroverse:42385.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF780315	viroverse:42396.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780316	viroverse:42397.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780317	viroverse:42398.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780318	viroverse:42399.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780319	viroverse:42400.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780320	viroverse:42401.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S
MF779828	viroverse:42439.1	USA	Jun-2000		genomic DNA	plasma from subject F6	days-post-seroconversion:286; viral-load:80;CD4-count:1790; CD8-count:964;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779151	viroverse:42476.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779152	viroverse:42477.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779153	viroverse:42478.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,12R,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779154	viroverse:42479.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779155	viroverse:42480.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779156	viroverse:42481.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779157	viroverse:42482.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779158	viroverse:42483.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779159	viroverse:42484.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779161	viroverse:42486.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779162	viroverse:42487.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779163	viroverse:42488.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779164	viroverse:42489.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779165	viroverse:42490.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779166	viroverse:42491.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779167	viroverse:42492.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779168	viroverse:42493.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779169	viroverse:42494.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D,216PS
MF779170	viroverse:42495.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779171	viroverse:42496.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,158M,180D
MF779172	viroverse:42497.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779173	viroverse:42498.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,72~,83L,91V,96L,116A,120A,123A,148V,180D
MF779174	viroverse:42499.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779175	viroverse:42500.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779176	viroverse:42501.1	USA	Jul-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:624; viral-load:83000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779360	viroverse:42525.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779361	viroverse:42526.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779362	viroverse:42527.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779363	viroverse:42528.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779364	viroverse:42529.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779365	viroverse:42530.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779366	viroverse:42531.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779367	viroverse:42532.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779368	viroverse:42533.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779369	viroverse:42534.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779370	viroverse:42535.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779371	viroverse:42536.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779372	viroverse:42537.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779373	viroverse:42538.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779374	viroverse:42539.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779375	viroverse:42540.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779376	viroverse:42541.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779377	viroverse:42542.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779378	viroverse:42543.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779379	viroverse:42544.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779380	viroverse:42545.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779381	viroverse:42546.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779382	viroverse:42547.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779383	viroverse:42548.1	USA	Apr-2005		genomic DNA	plasma from subject F3	days-post-seroconversion:998; viral-load:15000;CD4-count:383; CD8-count:883;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779856	viroverse:42573.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779857	viroverse:42574.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779858	viroverse:42575.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779859	viroverse:42576.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779860	viroverse:42577.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779861	viroverse:42578.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779862	viroverse:42579.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779863	viroverse:42580.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779864	viroverse:42581.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779865	viroverse:42582.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779866	viroverse:42583.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,195DN,208G
MF779867	viroverse:42584.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779868	viroverse:42585.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779869	viroverse:42586.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779870	viroverse:42587.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779871	viroverse:42588.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779872	viroverse:42589.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779873	viroverse:42590.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779874	viroverse:42591.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779875	viroverse:42592.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779876	viroverse:42593.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779877	viroverse:42594.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779878	viroverse:42595.1	USA	Jan-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:853; viral-load:1200;CD4-count:1197; CD8-count:632;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF780321	viroverse:42618.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780322	viroverse:42619.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,178T,183S,216S
MF780324	viroverse:42621.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780325	viroverse:42622.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780326	viroverse:42623.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780327	viroverse:42624.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780328	viroverse:42625.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780329	viroverse:42626.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780330	viroverse:42627.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780331	viroverse:42628.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780332	viroverse:42629.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF779713	viroverse:42630.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6L,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779714	viroverse:42631.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136I,141V,154K,178T
MF779715	viroverse:42632.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,97GR,116T,120S,126I,132K,136I,141V,154K
MF779716	viroverse:42633.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779717	viroverse:42634.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,212K
MF779718	viroverse:42635.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779719	viroverse:42636.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K
MF779720	viroverse:42637.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6L,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K
MF779721	viroverse:42638.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6L,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K
MF779722	viroverse:42639.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,195NS
MF779723	viroverse:42640.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779724	viroverse:42641.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779725	viroverse:42642.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K
MF779726	viroverse:42643.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K
MF779727	viroverse:42644.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K
MF779728	viroverse:42645.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6L,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K
MF779729	viroverse:42646.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T,199R
MF779730	viroverse:42647.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K
MF779731	viroverse:42648.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T,199R
MF779732	viroverse:42649.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,160S
MF779733	viroverse:42650.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,199R
MF779734	viroverse:42651.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779735	viroverse:42652.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K
MF779736	viroverse:42653.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779737	viroverse:42654.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K
MF779738	viroverse:42655.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779739	viroverse:42656.1	USA	May-1999		genomic DNA	plasma from subject F5	days-post-seroconversion:862; viral-load:12000;CD4-count:646; CD8-count:646;subtype: B	1	231	6L,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF780333	viroverse:42657.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780334	viroverse:42658.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,180D
MF780335	viroverse:42659.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF778840	viroverse:42667.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778841	viroverse:42669.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,14P,16A,44A,83L,120H,183D
MF778842	viroverse:42670.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778843	viroverse:42675.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,44A,83L,120H,148I
MF778844	viroverse:42677.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,44A,83L,120H,129IV,148I,151R
MF778862	viroverse:42696.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778863	viroverse:42697.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778864	viroverse:42698.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778865	viroverse:42699.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778866	viroverse:42700.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778867	viroverse:42701.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778868	viroverse:42702.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778869	viroverse:42703.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778870	viroverse:42704.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778871	viroverse:42705.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778872	viroverse:42706.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778873	viroverse:42707.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778874	viroverse:42708.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778875	viroverse:42709.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778876	viroverse:42710.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778877	viroverse:42711.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778878	viroverse:42712.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6V,83L,120H
MF780066	viroverse:42713.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780067	viroverse:42714.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780068	viroverse:42715.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780069	viroverse:42716.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780070	viroverse:42717.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780071	viroverse:42718.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780072	viroverse:42719.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780073	viroverse:42720.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780074	viroverse:42721.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780075	viroverse:42722.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,91V,98D,120S,180D,208G
MF780076	viroverse:42723.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780077	viroverse:42724.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50A,83L,87Q,91V,98D,120S,180D,208G
MF780078	viroverse:42731.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780079	viroverse:42734.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,91V,98D,120S,180D,208G
MF780080	viroverse:42735.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,55MV,83L,87Q,91V,98D,120S,180D,208G
MF780081	viroverse:42736.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780082	viroverse:42737.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,57D,83L,87Q,91V,98D,120S,180D,208G
MF780084	viroverse:42739.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780085	viroverse:42740.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780471	viroverse:42748.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780472	viroverse:42749.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780473	viroverse:42750.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83M,120S,148V,154K,178T,225S
MF780474	viroverse:42751.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780475	viroverse:42752.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780476	viroverse:42753.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780477	viroverse:42754.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780478	viroverse:42755.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,52X,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780479	viroverse:42756.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780480	viroverse:42757.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,223R,225S
MF780481	viroverse:42758.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780482	viroverse:42759.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,35*E,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780483	viroverse:42760.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780484	viroverse:42761.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83M,120S,148V,154K,178T,225S
MF780485	viroverse:42762.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780486	viroverse:42763.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780487	viroverse:42764.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780488	viroverse:42765.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF779528	viroverse:42773.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,19AT,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779529	viroverse:42775.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,55V,91V,120S,128D,148V,178T,199R,225S
MF779530	viroverse:42776.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779531	viroverse:42777.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779532	viroverse:42778.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,95QR,120S,128D,148V,178T,199R,225S
MF779533	viroverse:42779.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779548	viroverse:42814.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,154K,178T,199R,225S
MF779549	viroverse:42815.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,178T,199R,225S
MF779550	viroverse:42816.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779755	viroverse:42817.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6L,14P,16A,41A,83M,116A,132K,136M,141V,154K,199R
MF779551	viroverse:42818.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,178T,199R,225S
MF779756	viroverse:42819.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6M,14P,16A,41A,83M,116A,132K,136M,141V,154K,178T,199R
MF779757	viroverse:42820.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6L,14P,16A,41A,53S,83M,116A,132K,136M,141V,154K,199R
MF779552	viroverse:42821.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,178T,199R,225S
MF779553	viroverse:42822.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779554	viroverse:42823.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,178T,199R,225S
MF779758	viroverse:42824.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6L,14P,16A,41A,83M,116A,132K,136M,141V,154K,199R
MF779555	viroverse:42825.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF780191	viroverse:42826.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,110S,116A,120S
MF780192	viroverse:42828.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,116A,120S
MF780193	viroverse:42829.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,116A,120S
MF780194	viroverse:42831.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,110S,116A,120S
MF780195	viroverse:42833.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,116A,120S
MF780196	viroverse:42834.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,110S,116A,120S
MF780197	viroverse:42836.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,116A,120S
MF780198	viroverse:42837.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,110S,116A,120S
MF779759	viroverse:42838.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6M,14P,16A,41A,83M,116A,132K,136M,141V,154K,199R
MF780199	viroverse:42839.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,110S,116A,120S
MF779760	viroverse:42840.1	USA	Jul-2000		genomic DNA	plasma from subject F5	days-post-seroconversion:1284; viral-load:1600000;CD4-count:658; CD8-count:527;subtype: B	1	231	6M,14P,16A,19AT,41A,83M,116A,132K,136M,141V,154K,199R
MF779222	viroverse:42857.1	USA	Jul-2002		genomic DNA	plasma from subject F2	days-post-seroconversion:1343; viral-load:250000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779556	viroverse:42858.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,178T,199R,225S
MF779557	viroverse:42859.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,178T,199R,225S
MF779558	viroverse:42860.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779559	viroverse:42861.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779560	viroverse:42862.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,178T,199R,225S
MF780200	viroverse:42871.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,110S,116A,120S,145C
MF780201	viroverse:42872.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,116A,120S
MF780202	viroverse:42873.1	USA	Oct-2003		genomic DNA	plasma from subject F7	days-post-seroconversion:1048; viral-load:97000;CD4-count:803; CD8-count:865;subtype: B	1	231	6S,50H,91V,110S,116A,120S
MF780408	viroverse:42877.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,15L,54L,79D,83M,148I,154K,178T,210S,225S
MF780409	viroverse:42878.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF778879	viroverse:42903.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778880	viroverse:42904.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF778881	viroverse:42907.1	USA	Apr-1999		genomic DNA	plasma from subject F1	days-post-seroconversion:1200; viral-load:3200;CD4-count:359; CD8-count:412;subtype: B	1	231	6L,83L,120H
MF780489	viroverse:42919.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780490	viroverse:42920.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,215I,225S
MF780491	viroverse:42921.1	USA	Aug-2001		genomic DNA	plasma from subject F8	days-post-seroconversion:1950; viral-load:2700;CD4-count:305; CD8-count:789;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780410	viroverse:42924.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,16T,27I,54L,79D,83M,96I,120S,148I,154K,178T,225S
MF780411	viroverse:42925.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,210S,225S
MF780412	viroverse:42926.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,210S,225S
MF780413	viroverse:42927.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF780414	viroverse:42928.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF780415	viroverse:42929.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,16T,27I,54L,79D,83M,96I,120S,148I,154K,178T,225S
MF780416	viroverse:42930.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,15L,54L,79D,83M,148I,154K,178T,210S,225S
MF780417	viroverse:42931.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780418	viroverse:42932.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,148I,154K,178T,210S,225S
MF780419	viroverse:42934.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,210S,225S
MF780420	viroverse:42935.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,210S,225S
MF780421	viroverse:42936.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780422	viroverse:42940.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,210S,225S
MF780423	viroverse:42941.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,15L,54L,79D,83M,148I,154K,178T,210S,225S
MF780424	viroverse:42945.1	USA	Dec-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:255; viral-load:19000;CD4-count:493; CD8-count:1027;subtype: B	1	231	6L,15L,54L,79D,83M,148I,154K,178T,210S,225S
MF780336	viroverse:42978.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780337	viroverse:42979.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,23*W,50H,91V,116A,120S,178T,216S
MF780338	viroverse:42980.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116T,120S,216S
MF780339	viroverse:42981.1	USA	Oct-2009		genomic DNA	plasma from subject F7	days-post-seroconversion:3237; viral-load:3556;CD4-count:763; CD8-count:824;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780086	viroverse:42982.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780087	viroverse:42983.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,137E,180D,208G
MF780088	viroverse:42984.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780089	viroverse:42985.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780090	viroverse:42986.1	USA	May-2011		genomic DNA	plasma from subject F6	days-post-seroconversion:4267; viral-load:;subtype: B	1	231	6L,14N,50T,83L,91V,98D,120S,180D,208G
MF778882	viroverse:42999.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L
MF778883	viroverse:43000.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L,120H
MF778884	viroverse:43001.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L,120H
MF778885	viroverse:43002.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L,120H
MF778886	viroverse:43003.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L
MF778887	viroverse:43004.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L,120H
MF778888	viroverse:43005.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L,120H
MF778889	viroverse:43006.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L,120H
MF778890	viroverse:43007.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,14V,83L
MF778891	viroverse:43008.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,27I,83L,120H,148I,154K
MF778892	viroverse:43009.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L,120H
MF778893	viroverse:43010.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L
MF778894	viroverse:43011.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L,120H
MF778895	viroverse:43012.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,78V,83L,120H
MF778896	viroverse:43013.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L
MF778897	viroverse:43014.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L
MF778898	viroverse:43015.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L,120H
MF778899	viroverse:43016.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L,120H
MF778900	viroverse:43017.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L,120H
MF778901	viroverse:43018.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L
MF778902	viroverse:43019.1	USA	Apr-2000		genomic DNA	plasma from subject F1	days-post-seroconversion:1570; viral-load:3200;CD4-count:282; CD8-count:444;subtype: B	1	231	6L,83L,115IT,120H
MF779534	viroverse:43034.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779535	viroverse:43036.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779536	viroverse:43037.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779537	viroverse:43038.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,159G,178T,199R,225S
MF779538	viroverse:43039.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779539	viroverse:43040.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91A,120S,128D,148V,178T,199R,225S
MF779540	viroverse:43041.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779541	viroverse:43042.1	USA	Apr-2006		genomic DNA	plasma from subject F4	days-post-seroconversion:1326; viral-load:6600;CD4-count:294; CD8-count:237;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,178T,199R,225S
MF779761	viroverse:43044.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,183S,199R
MF779762	viroverse:43045.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,199R
MF779384	viroverse:43046.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779763	viroverse:43049.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6L,14P,16A,41A,83M,116A,132K,136M,141V,154K,178T,199R
MF779386	viroverse:43080.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779387	viroverse:43083.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779388	viroverse:43085.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779389	viroverse:43086.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,68T,71D,83L
MF780539	viroverse:43089.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780540	viroverse:43090.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780541	viroverse:43091.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780542	viroverse:43092.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780543	viroverse:43093.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,16T,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780544	viroverse:43094.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780545	viroverse:43095.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780546	viroverse:43096.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780547	viroverse:43097.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,16T,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780548	viroverse:43098.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780549	viroverse:43099.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780550	viroverse:43100.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,138~,139~,140~,141~,142~,143~,148V,154K,178T,225S
MF780118	viroverse:43111.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,27I,50H,91V,110N,116A,120S
MF780119	viroverse:43112.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780120	viroverse:43113.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780121	viroverse:43114.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,27I,50H,91V,110N,116A,120S
MF780122	viroverse:43115.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,27I,50H,91V,110N,116A,120S
MF780123	viroverse:43117.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,27I,50H,91V,110N,116A,120S
MF780124	viroverse:43118.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780125	viroverse:43119.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780126	viroverse:43120.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780127	viroverse:43121.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780128	viroverse:43122.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF778820	viroverse:43130.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,44A,83L,120H
MF778821	viroverse:43131.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778822	viroverse:43132.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,44A,83L,120H
MF778823	viroverse:43133.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778824	viroverse:43134.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778825	viroverse:43135.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778826	viroverse:43136.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778827	viroverse:43137.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778828	viroverse:43138.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,44A,83L,120H
MF778829	viroverse:43139.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778830	viroverse:43140.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778831	viroverse:43141.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,44A,83L,120H
MF778832	viroverse:43162.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778833	viroverse:43163.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778834	viroverse:43164.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,44A,83L,120H
MF778835	viroverse:43165.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778836	viroverse:43166.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,44A,83L,120H
MF778837	viroverse:43167.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778838	viroverse:43168.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,44A,83L,120H
MF778839	viroverse:43169.1	USA	Apr-1997		genomic DNA	plasma from subject F1	days-post-seroconversion:458; viral-load:1592;CD4-count:328; CD8-count:337;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF780551	viroverse:43170.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780552	viroverse:43171.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780553	viroverse:43172.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780554	viroverse:43173.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780555	viroverse:43174.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,16T,27I,54L,79D,83T,87Q,91V,120S,148V,154K,178T,225S
MF780556	viroverse:43175.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780557	viroverse:43176.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780558	viroverse:43177.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,27I,43LS,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780559	viroverse:43178.1	USA	Mar-2005		genomic DNA	plasma from subject F8	days-post-seroconversion:3259; viral-load:26000;CD4-count:57; CD8-count:912;subtype: B	1	231	6L,14S,15L,16T,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF779829	viroverse:43200.1	USA	Jun-2000		genomic DNA	plasma from subject F6	days-post-seroconversion:286; viral-load:80;CD4-count:1790; CD8-count:964;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779311	viroverse:43201.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,67QR,71D,83L
MF779312	viroverse:43202.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779313	viroverse:43203.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779314	viroverse:43204.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779315	viroverse:43205.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779316	viroverse:43206.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779317	viroverse:43207.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779318	viroverse:43208.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779319	viroverse:43209.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,9P,11T,15L,50H,71D,83L
MF779320	viroverse:43210.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779321	viroverse:43211.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779322	viroverse:43212.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779323	viroverse:43213.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L,128K,187K
MF779324	viroverse:43214.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779325	viroverse:43215.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779326	viroverse:43216.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779327	viroverse:43217.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779328	viroverse:43218.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779329	viroverse:43219.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779330	viroverse:43220.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L,124IT
MF779331	viroverse:43221.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779332	viroverse:43222.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D
MF779333	viroverse:43223.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779177	viroverse:43247.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779178	viroverse:43248.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,107ST,116A,120A,123A,148V,180D
MF779179	viroverse:43249.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779180	viroverse:43250.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779181	viroverse:43251.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779182	viroverse:43252.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,102N,116A,120A,123A,148V,180D
MF779183	viroverse:43253.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779184	viroverse:43254.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779185	viroverse:43255.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779186	viroverse:43256.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779187	viroverse:43257.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779188	viroverse:43258.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779189	viroverse:43259.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,70Q,83L,91V,96L,116A,120A,123A,148V,180D
MF779190	viroverse:43260.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779191	viroverse:43261.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779192	viroverse:43262.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,96L,116A,120A,123A,148V,180D
MF779193	viroverse:43263.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779194	viroverse:43264.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779195	viroverse:43265.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779196	viroverse:43266.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779197	viroverse:43267.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779198	viroverse:43268.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF778845	viroverse:43273.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,44A,83L,120H,148I
MF778846	viroverse:43274.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778847	viroverse:43278.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,44A,83L,120H,148I
MF779691	viroverse:43303.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779692	viroverse:43304.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6L,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779693	viroverse:43305.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779694	viroverse:43306.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779695	viroverse:43307.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779696	viroverse:43308.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,16A,41A,83M,115IV,116T,120S,126I,132K,136M,141V,154K,178T
MF779697	viroverse:43309.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,146N,154K,178T
MF779698	viroverse:43310.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779699	viroverse:43311.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779700	viroverse:43312.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6L,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779701	viroverse:43313.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6L,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779703	viroverse:43315.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779704	viroverse:43316.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779705	viroverse:43317.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,15L,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779706	viroverse:43318.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6L,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779707	viroverse:43319.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779708	viroverse:43320.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6L,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779709	viroverse:43321.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779764	viroverse:43345.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6M,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R
MF779765	viroverse:43346.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6L,14P,16A,41A,83M,116A,132K,136M,141V,154K,178T,199R
MF779766	viroverse:43347.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6M,14P,16A,41A,83M,116A,132K,136M,141V,154K,199R
MF779767	viroverse:43348.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6L,14P,16A,41A,83M,116A,132K,136I,141V,154K,178T,199R
MF779768	viroverse:43349.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R
MF779769	viroverse:43350.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6M,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R
MF779770	viroverse:43351.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R
MF779771	viroverse:43352.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6L,14P,16A,41A,83M,116A,132K,136M,141V,154K,178T,199R
MF779561	viroverse:43353.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,154K,199R,225S
MF779772	viroverse:43354.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R
MF779773	viroverse:43355.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6L,14P,16A,41A,83M,116A,132K,136M,141V,154K,178T,199R
MF779562	viroverse:43356.1	USA	Apr-2007		genomic DNA	plasma from subject F4	days-post-seroconversion:1689; viral-load:9300;CD4-count:184; CD8-count:179;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,154K,199R,225S
MF779774	viroverse:43357.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	4QR,6L,14P,16A,41A,83M,116A,132K,136I,141V,154K,178T,199R
MF779775	viroverse:43358.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R
MF779776	viroverse:43359.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R
MF779390	viroverse:43360.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L,154G
MF779777	viroverse:43361.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6M,14P,16A,41A,83M,116A,132K,136I,141V,154K,178T,199R
MF779778	viroverse:43362.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6M,14P,16A,41A,83M,116A,132K,136M,141V,154K,178T,199R
MF779391	viroverse:43363.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779779	viroverse:43364.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R
MF779392	viroverse:43365.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L,229K
MF779393	viroverse:43366.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779394	viroverse:43367.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779395	viroverse:43368.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779780	viroverse:43369.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6M,14P,16A,41A,83M,116A,132K,136M,141V,154K,178T,199R
MF779396	viroverse:43370.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779397	viroverse:43373.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L,90PS
MF779199	viroverse:43400.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779710	viroverse:43401.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,16T,41A,83M,91IT,116T,120S,126I,132K,136M,141V,154K,178T
MF779334	viroverse:43402.1	USA	Oct-2003		genomic DNA	plasma from subject F3	days-post-seroconversion:451; viral-load:45000;CD4-count:573; CD8-count:1126;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779200	viroverse:43405.1	USA	Jul-2001		genomic DNA	plasma from subject F2	days-post-seroconversion:986; viral-load:170000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779711	viroverse:43406.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779712	viroverse:43407.1	USA	Nov-1998		genomic DNA	plasma from subject F5	days-post-seroconversion:681; viral-load:53000;CD4-count:920; CD8-count:797;subtype: B	1	231	6M,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF778848	viroverse:43408.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778849	viroverse:43409.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,83L,120H
MF778850	viroverse:43410.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778851	viroverse:43412.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,44A,83L,120H
MF778852	viroverse:43413.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778853	viroverse:43414.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778854	viroverse:43415.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,44A,83L,120H
MF778855	viroverse:43416.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,44A,83L,120H
MF778856	viroverse:43417.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778857	viroverse:43419.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778858	viroverse:43421.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,83L,120H
MF778859	viroverse:43422.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,44A,83L,120H
MF778860	viroverse:43423.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,14P,16A,44A,83L,120H
MF778861	viroverse:43424.1	USA	Mar-1998		genomic DNA	plasma from subject F1	days-post-seroconversion:807; viral-load:4800;CD4-count:374; CD8-count:444;subtype: B	1	231	6L,44A,83L,120H,148I
MF780129	viroverse:43438.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780130	viroverse:43440.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780131	viroverse:43442.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780132	viroverse:43443.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,27I,50H,91V,110N,116A,120S
MF780133	viroverse:43444.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780492	viroverse:43451.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780493	viroverse:43452.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780494	viroverse:43453.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780495	viroverse:43454.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780496	viroverse:43455.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780497	viroverse:43456.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780498	viroverse:43457.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780499	viroverse:43458.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780500	viroverse:43459.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780501	viroverse:43460.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780502	viroverse:43461.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780503	viroverse:43462.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780504	viroverse:43495.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780505	viroverse:43496.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780506	viroverse:43497.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF779901	viroverse:43514.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779902	viroverse:43515.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779903	viroverse:43517.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779904	viroverse:43518.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779905	viroverse:43520.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779906	viroverse:43522.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF780451	viroverse:43524.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF780452	viroverse:43525.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF780453	viroverse:43526.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF780454	viroverse:43527.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148V,154K,178T,225S
MF780455	viroverse:43528.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF780456	viroverse:43529.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780457	viroverse:43530.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83M,111F,120S,148V,154K,178T,225S
MF780458	viroverse:43532.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780459	viroverse:43533.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF780460	viroverse:43534.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780461	viroverse:43535.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF780462	viroverse:43536.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF780463	viroverse:43537.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF780464	viroverse:43538.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,133*,148I,154K,178T,225S
MF780465	viroverse:43539.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780466	viroverse:43540.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF780467	viroverse:43541.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF780468	viroverse:43542.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF779907	viroverse:43555.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779908	viroverse:43556.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779909	viroverse:43557.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779910	viroverse:43558.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779911	viroverse:43559.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779912	viroverse:43560.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779913	viroverse:43561.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779914	viroverse:43562.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779915	viroverse:43563.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779916	viroverse:43564.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779917	viroverse:43565.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779223	viroverse:43567.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779224	viroverse:43568.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779225	viroverse:43569.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779226	viroverse:43570.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779227	viroverse:43571.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,88S,91A,96L,116A,120A,123A,148V,180D
MF779228	viroverse:43572.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779229	viroverse:43573.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779230	viroverse:43574.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779231	viroverse:43575.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779232	viroverse:43576.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779233	viroverse:43577.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779234	viroverse:43578.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779235	viroverse:43579.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779236	viroverse:43580.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779237	viroverse:43581.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779238	viroverse:43582.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779239	viroverse:43583.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779240	viroverse:43584.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779241	viroverse:43585.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779242	viroverse:43586.1	USA	Nov-2003		genomic DNA	plasma from subject F2	days-post-seroconversion:1833; viral-load:950000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF780507	viroverse:43607.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780508	viroverse:43608.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780509	viroverse:43609.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780510	viroverse:43610.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780511	viroverse:43611.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780512	viroverse:43612.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780513	viroverse:43613.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780514	viroverse:43614.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF780515	viroverse:43615.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780516	viroverse:43616.1	USA	Feb-2002		genomic DNA	plasma from subject F8	days-post-seroconversion:2146; viral-load:6300;CD4-count:340; CD8-count:1021;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,148V,154K,178T,225S
MF779104	viroverse:43620.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779105	viroverse:43621.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779106	viroverse:43622.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779107	viroverse:43623.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779108	viroverse:43624.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779109	viroverse:43625.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779110	viroverse:43626.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779111	viroverse:43627.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779781	viroverse:43652.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,199R
MF779782	viroverse:43653.1	USA	Apr-2001		genomic DNA	plasma from subject F5	days-post-seroconversion:1542; viral-load:64000;CD4-count:501; CD8-count:744;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,199R
MF779398	viroverse:43657.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779563	viroverse:43658.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,154K,178T,199R,225S
MF778924	viroverse:43659.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,83L
MF779399	viroverse:43660.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF778925	viroverse:43661.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,148I
MF779400	viroverse:43662.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779401	viroverse:43663.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779402	viroverse:43664.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779403	viroverse:43665.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779404	viroverse:43666.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779405	viroverse:43667.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779406	viroverse:43668.1	USA	Apr-2006		genomic DNA	plasma from subject F3	days-post-seroconversion:1369; viral-load:37000;CD4-count:281; CD8-count:1159;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779243	viroverse:43706.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779244	viroverse:43707.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779245	viroverse:43708.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779246	viroverse:43709.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779247	viroverse:43710.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779248	viroverse:43711.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779249	viroverse:43712.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779250	viroverse:43713.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779251	viroverse:43714.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779252	viroverse:43715.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779253	viroverse:43716.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779254	viroverse:43717.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779255	viroverse:43724.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779256	viroverse:43726.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779257	viroverse:43727.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779258	viroverse:43730.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779259	viroverse:43732.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779260	viroverse:43734.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779261	viroverse:43736.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,14V,27I,83L,91A,96L,116A,120A,123A,148V,155H,180D
MF779262	viroverse:43738.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779263	viroverse:43740.1	USA	May-2004		genomic DNA	plasma from subject F2	days-post-seroconversion:2017; viral-load:1400000;subtype: B	1	231	6L,27I,83L,91A,96L,116A,120A,123A,148V,180D
MF779112	viroverse:43741.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779113	viroverse:43742.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779114	viroverse:43743.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,109G,116A,120A,123A,148V,180D
MF779115	viroverse:43744.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779116	viroverse:43745.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779117	viroverse:43746.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779119	viroverse:43748.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779120	viroverse:43749.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779121	viroverse:43750.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D,191IV
MF779122	viroverse:43751.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779123	viroverse:43752.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF778926	viroverse:43755.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,148I
MF778927	viroverse:43759.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,148I
MF778928	viroverse:43760.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,148I
MF778929	viroverse:43761.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,148I,178T
MF779124	viroverse:43762.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D,208T
MF779125	viroverse:43763.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779126	viroverse:43764.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779127	viroverse:43765.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779128	viroverse:43766.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779129	viroverse:43767.1	USA	Jul-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:274; viral-load:230;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF780425	viroverse:43768.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780426	viroverse:43769.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83M,120S,148I,154K,178T,210S,225S
MF780427	viroverse:43770.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780428	viroverse:43771.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,148I,154K,178T,225S
MF780429	viroverse:43772.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780430	viroverse:43773.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,148I,154K,178T,225S
MF780431	viroverse:43774.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,14S,15L,27I,44T,54L,79D,83T,148I,154K,178T,210S,225S
MF780432	viroverse:43775.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,148I,154K,178T,225S
MF780433	viroverse:43776.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780434	viroverse:43777.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780435	viroverse:43778.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,148I,154K,178T,210S,225S
MF780436	viroverse:43779.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780437	viroverse:43780.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780438	viroverse:43781.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,148I,154K,178T,225S
MF780439	viroverse:43782.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780440	viroverse:43783.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,148I,154K,178T,225S
MF780441	viroverse:43784.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780442	viroverse:43785.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF780443	viroverse:43786.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780444	viroverse:43787.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780445	viroverse:43788.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,91V,148I,154K,178T,225S
MF780446	viroverse:43789.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780447	viroverse:43790.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780448	viroverse:43791.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83M,94S,120S,148I,154K,178T,225S
MF780449	viroverse:43792.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780450	viroverse:43793.1	USA	Jun-1997		genomic DNA	plasma from subject F8	days-post-seroconversion:438; viral-load:17453;CD4-count:427; CD8-count:1153;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,148I,154K,178T,225S
MF779808	viroverse:43816.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779809	viroverse:43817.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,199R,216S
MF779810	viroverse:43818.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779811	viroverse:43819.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R
MF779812	viroverse:43820.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,199R
MF779813	viroverse:43821.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,100K,116A,132K,133*,136M,141V,154K,178T,199R,216S
MF779814	viroverse:43822.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779815	viroverse:43823.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R,229K
MF779816	viroverse:43824.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R
MF779817	viroverse:43825.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779818	viroverse:43826.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,199R,216S
MF779879	viroverse:43827.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779880	viroverse:43828.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779881	viroverse:43829.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779882	viroverse:43830.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779883	viroverse:43831.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779884	viroverse:43832.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779885	viroverse:43833.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G,210AT
MF779886	viroverse:43834.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779887	viroverse:43835.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779888	viroverse:43836.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779889	viroverse:43837.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779890	viroverse:43838.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779891	viroverse:43839.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779892	viroverse:43841.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779893	viroverse:43842.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779894	viroverse:43843.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779895	viroverse:43844.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779896	viroverse:43845.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779897	viroverse:43846.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779898	viroverse:43847.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779899	viroverse:43848.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779972	viroverse:43870.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779973	viroverse:43871.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779974	viroverse:43872.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,128K,180D,208G
MF779975	viroverse:43873.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779976	viroverse:43874.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779977	viroverse:43875.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779978	viroverse:43876.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779979	viroverse:43877.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779980	viroverse:43878.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779981	viroverse:43879.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779982	viroverse:43880.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779983	viroverse:43881.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779984	viroverse:43882.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,27I,50T,83L,87Q,91V,98D,120S,180D,208G
MF779985	viroverse:43883.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779986	viroverse:43884.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779987	viroverse:43885.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,110AT,120S,180D,208G
MF779988	viroverse:43886.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779989	viroverse:43887.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779990	viroverse:43888.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779991	viroverse:43889.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779992	viroverse:43890.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779993	viroverse:43891.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779994	viroverse:43892.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779995	viroverse:43893.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779996	viroverse:43896.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779997	viroverse:43897.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779998	viroverse:43898.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,66I,83L,87Q,91V,98D,120S,180D,208G
MF779999	viroverse:43900.1	USA	Nov-2006		genomic DNA	plasma from subject F6	days-post-seroconversion:2632; viral-load:2300;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF778930	viroverse:43917.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,97K,148V,178T
MF778931	viroverse:43918.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,83L
MF778932	viroverse:43919.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,148I
MF778933	viroverse:43920.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,148I
MF778934	viroverse:43921.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L
MF778935	viroverse:43922.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,148I
MF778936	viroverse:43923.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,148I
MF778937	viroverse:43924.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,148I
MF779564	viroverse:43925.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,154K,199R,225S
MF779565	viroverse:43927.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,199R,225S
MF779566	viroverse:43928.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779567	viroverse:43929.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91A,120S,128D,148V,154K,178T,199R,225S
MF779568	viroverse:43930.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,154K,199R,225S
MF778938	viroverse:43931.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,148I
MF778939	viroverse:43932.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,120H,148I,154K
MF778940	viroverse:43933.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,148I
MF778941	viroverse:43934.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,148I
MF778942	viroverse:43935.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,148I
MF778943	viroverse:43936.1	USA	Apr-2002		genomic DNA	plasma from subject F1	days-post-seroconversion:2297; viral-load:7400;CD4-count:168; CD8-count:292;subtype: B	1	231	6L,27I,83L,148I
MF779335	viroverse:43937.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779336	viroverse:43938.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779337	viroverse:43939.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779338	viroverse:43940.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779339	viroverse:43941.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779340	viroverse:43942.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779341	viroverse:43943.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779342	viroverse:43944.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779343	viroverse:43945.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779344	viroverse:43946.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779345	viroverse:43947.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779346	viroverse:43948.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779347	viroverse:43949.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779348	viroverse:43950.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779349	viroverse:43952.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779350	viroverse:43953.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779351	viroverse:43954.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779352	viroverse:43955.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779353	viroverse:43956.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779354	viroverse:43957.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779355	viroverse:43958.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779356	viroverse:43959.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779357	viroverse:43960.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779358	viroverse:43961.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779359	viroverse:43962.1	USA	Apr-2004		genomic DNA	plasma from subject F3	days-post-seroconversion:634; viral-load:28000;CD4-count:487; CD8-count:1123;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF780295	viroverse:43995.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780297	viroverse:43997.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780298	viroverse:43998.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780299	viroverse:43999.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780300	viroverse:44000.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780301	viroverse:44001.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780302	viroverse:44002.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780303	viroverse:44003.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780304	viroverse:44004.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780305	viroverse:44005.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780306	viroverse:44006.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780307	viroverse:44007.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780308	viroverse:44008.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780309	viroverse:44009.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780310	viroverse:44010.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780311	viroverse:44011.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780312	viroverse:44012.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,180D,216S
MF780313	viroverse:44013.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780314	viroverse:44014.1	USA	Oct-2008		genomic DNA	plasma from subject F7	days-post-seroconversion:2867; viral-load:6601;CD4-count:580; CD8-count:660;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF779130	viroverse:44032.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779131	viroverse:44033.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779132	viroverse:44034.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779133	viroverse:44035.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779134	viroverse:44036.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779135	viroverse:44037.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779136	viroverse:44038.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779137	viroverse:44039.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779138	viroverse:44040.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779139	viroverse:44041.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,11AV,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779140	viroverse:44042.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779141	viroverse:44043.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779142	viroverse:44044.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779143	viroverse:44045.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779144	viroverse:44046.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779145	viroverse:44047.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779146	viroverse:44048.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779147	viroverse:44049.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779148	viroverse:44050.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779149	viroverse:44051.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779150	viroverse:44052.1	USA	Jan-2000		genomic DNA	plasma from subject F2	days-post-seroconversion:442; viral-load:190000;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF780517	viroverse:44113.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,16T,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780518	viroverse:44114.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,16T,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780519	viroverse:44115.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,16T,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780520	viroverse:44116.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,16T,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780521	viroverse:44117.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780522	viroverse:44118.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780523	viroverse:44119.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,16T,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780524	viroverse:44120.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780525	viroverse:44121.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780526	viroverse:44122.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780527	viroverse:44123.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,16T,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780528	viroverse:44124.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,16T,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780529	viroverse:44125.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780530	viroverse:44126.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,16T,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780531	viroverse:44127.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,212G,225S
MF780532	viroverse:44128.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780533	viroverse:44129.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,16T,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780535	viroverse:44131.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780536	viroverse:44132.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780134	viroverse:44133.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780537	viroverse:44135.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780135	viroverse:44136.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780538	viroverse:44137.1	USA	Mar-2004		genomic DNA	plasma from subject F8	days-post-seroconversion:2902; viral-load:11000;CD4-count:128; CD8-count:1064;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780136	viroverse:44139.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,27I,50H,74DN,91V,110N,116A,120S
MF780137	viroverse:44142.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780138	viroverse:44143.1	USA	Nov-2001		genomic DNA	plasma from subject F7	days-post-seroconversion:355; viral-load:710;CD4-count:1328; CD8-count:1292;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780382	viroverse:44146.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,15L,27I,36IV,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780383	viroverse:44149.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780384	viroverse:44151.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780385	viroverse:44152.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780386	viroverse:44153.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780387	viroverse:44154.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF779918	viroverse:44156.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779919	viroverse:44157.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779921	viroverse:44159.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779922	viroverse:44160.1	USA	Nov-2003		genomic DNA	plasma from subject F6	days-post-seroconversion:1524; viral-load:8800;CD4-count:601; CD8-count:388;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779830	viroverse:44161.1	USA	Nov-2000		genomic DNA	plasma from subject F6	days-post-seroconversion:445; viral-load:140;CD4-count:1853; CD8-count:943;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779831	viroverse:44162.1	USA	Nov-2000		genomic DNA	plasma from subject F6	days-post-seroconversion:445; viral-load:140;CD4-count:1853; CD8-count:943;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779832	viroverse:44163.1	USA	Nov-2000		genomic DNA	plasma from subject F6	days-post-seroconversion:445; viral-load:140;CD4-count:1853; CD8-count:943;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779833	viroverse:44164.1	USA	Nov-2000		genomic DNA	plasma from subject F6	days-post-seroconversion:445; viral-load:140;CD4-count:1853; CD8-count:943;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779834	viroverse:44165.1	USA	Nov-2000		genomic DNA	plasma from subject F6	days-post-seroconversion:445; viral-load:140;CD4-count:1853; CD8-count:943;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779449	viroverse:44166.1	USA	Apr-2008		genomic DNA	plasma from subject F3	days-post-seroconversion:2105; viral-load:80;CD4-count:203; CD8-count:652;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779459	viroverse:44168.1	USA	May-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:261; viral-load:80;CD4-count:577; CD8-count:301;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779460	viroverse:44169.1	USA	May-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:261; viral-load:80;CD4-count:577; CD8-count:301;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779450	viroverse:44170.1	USA	Apr-2008		genomic DNA	plasma from subject F3	days-post-seroconversion:2105; viral-load:80;CD4-count:203; CD8-count:652;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF780388	viroverse:44177.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780389	viroverse:44180.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780390	viroverse:44183.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780391	viroverse:44184.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,15IL,27I,54L,83M,96I,148I,154K,178T,210S,225S
MF780392	viroverse:44186.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780393	viroverse:44187.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780394	viroverse:44188.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF778779	viroverse:44219.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H,195KN
MF778780	viroverse:44220.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF778781	viroverse:44221.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF778782	viroverse:44222.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF778783	viroverse:44223.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF780469	viroverse:44226.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83M,120S,148I,154K,178T,225S
MF779584	viroverse:44252.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779585	viroverse:44253.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779586	viroverse:44254.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779587	viroverse:44255.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779588	viroverse:44256.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779589	viroverse:44257.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779590	viroverse:44258.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779591	viroverse:44259.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779592	viroverse:44260.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779593	viroverse:44261.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779594	viroverse:44262.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,98V,120S,128D,148V,154K,178T,199R,225S
MF779595	viroverse:44263.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779596	viroverse:44264.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779597	viroverse:44265.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779598	viroverse:44266.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779599	viroverse:44267.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779600	viroverse:44268.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779601	viroverse:44269.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779602	viroverse:44270.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779603	viroverse:44271.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,87Q,91V,120S,128D,148V,154K,178T,199R,225S
MF779604	viroverse:44272.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779605	viroverse:44273.1	USA	Apr-2009		genomic DNA	plasma from subject F4	days-post-seroconversion:2419; viral-load:1250;CD4-count:213; CD8-count:347;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF780226	viroverse:44276.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,9QR,50H,91V,116A,120S,216S
MF780227	viroverse:44277.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780228	viroverse:44278.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780229	viroverse:44279.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,116A,120S
MF780230	viroverse:44280.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,116A,120S
MF780231	viroverse:44281.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780232	viroverse:44282.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780233	viroverse:44283.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780234	viroverse:44284.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,53NS,91V,116A,120S,216S
MF780235	viroverse:44285.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,116A,120S
MF780236	viroverse:44286.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,97K,116A,120S,216S
MF780237	viroverse:44287.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,116A,120S,178T
MF780238	viroverse:44288.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,116A,120S,216S
MF780239	viroverse:44289.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780240	viroverse:44290.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,73IV,91V,116A,120S,216S
MF780241	viroverse:44291.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780242	viroverse:44292.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780243	viroverse:44293.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,102GS,116A,120S
MF780244	viroverse:44294.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780245	viroverse:44295.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780246	viroverse:44296.1	USA	Oct-2005		genomic DNA	plasma from subject F7	days-post-seroconversion:1761; viral-load:16000;CD4-count:931; CD8-count:1005;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF779819	viroverse:44322.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779820	viroverse:44323.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,199R,216S
MF779821	viroverse:44324.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R
MF779822	viroverse:44325.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779823	viroverse:44326.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R,229K
MF779824	viroverse:44329.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,180D,199R,216S
MF779825	viroverse:44330.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,101E,116A,132K,136M,141V,154K,178T,199R,216S
MF779648	viroverse:44351.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6L,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779649	viroverse:44352.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779650	viroverse:44353.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6L,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779651	viroverse:44354.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6M,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779652	viroverse:44355.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6L,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779653	viroverse:44356.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6L,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779654	viroverse:44357.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6L,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779655	viroverse:44358.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6L,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779656	viroverse:44359.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6L,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779657	viroverse:44360.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	3I,6M,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779658	viroverse:44361.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779659	viroverse:44362.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	3I,6M,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779660	viroverse:44363.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6M,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779661	viroverse:44364.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6L,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779662	viroverse:44365.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6M,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779663	viroverse:44366.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6L,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779664	viroverse:44367.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6M,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779665	viroverse:44368.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6M,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779666	viroverse:44369.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6L,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779667	viroverse:44370.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6M,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779668	viroverse:44371.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6L,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779669	viroverse:44372.1	USA	Apr-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:87; viral-load:39000;CD4-count:836; CD8-count:727;subtype: B	1	231	6L,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779428	viroverse:44393.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779429	viroverse:44394.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779430	viroverse:44395.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779431	viroverse:44396.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779432	viroverse:44397.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779433	viroverse:44398.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779434	viroverse:44399.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779435	viroverse:44400.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779436	viroverse:44401.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779437	viroverse:44402.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779438	viroverse:44403.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779439	viroverse:44404.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779440	viroverse:44405.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I,212G
MF779441	viroverse:44406.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779442	viroverse:44407.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779443	viroverse:44408.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779444	viroverse:44409.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779445	viroverse:44410.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779446	viroverse:44411.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I,106*GR,148INST,153IM,155LPQR
MF779447	viroverse:44412.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779448	viroverse:44413.1	USA	Oct-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1917; viral-load:66000;CD4-count:188; CD8-count:1111;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779627	viroverse:44438.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779628	viroverse:44439.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,154K,199R,225S
MF779629	viroverse:44440.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779630	viroverse:44441.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779631	viroverse:44442.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,98G,120S,128D,148V,154K,178T,199R,225S
MF779632	viroverse:44443.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779633	viroverse:44444.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779634	viroverse:44445.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779635	viroverse:44446.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779636	viroverse:44447.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,180D,199R,225S
MF779637	viroverse:44448.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779638	viroverse:44449.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779639	viroverse:44450.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779640	viroverse:44451.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779641	viroverse:44452.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779642	viroverse:44453.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779644	viroverse:44455.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779645	viroverse:44456.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779646	viroverse:44457.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,183S,199R,225S
MF779647	viroverse:44458.1	USA	Oct-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2970; viral-load:2470;CD4-count:166; CD8-count:272;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779035	viroverse:44481.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,83L,148V,183G,208G
MF779036	viroverse:44482.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,83L,148V,183G,191I,208G
MF779037	viroverse:44483.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,83L,148V,183G,191I,208G
MF779038	viroverse:44484.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,27I,83L,148V
MF779039	viroverse:44485.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,27I,83L,148V,183G,208G
MF779040	viroverse:44486.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,83L,148V,183G,208G
MF779041	viroverse:44487.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,27I,83L,148V,183G,208G
MF779043	viroverse:44489.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,83L,148V,183G,191I,208G
MF779044	viroverse:44490.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,83L,148V,183G,191I,208G
MF779046	viroverse:44492.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,27I,83L,148V,183G,208G
MF779047	viroverse:44494.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,27I,83L,148V,208G
MF779048	viroverse:44495.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,83L,148V,183G,208G
MF779049	viroverse:44496.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,83L,148V,183G,208G
MF779050	viroverse:44497.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,27I,83L,148V
MF779051	viroverse:44498.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	3X,4X,6L,27I,83L,148V,183G,208G
MF779052	viroverse:44499.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,83L,148V,183G,208G
MF779053	viroverse:44500.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,83L,148V,183G,208G
MF779054	viroverse:44501.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,83L,148V,183G,208G
MF779055	viroverse:44502.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,27I,83L,148V,208G
MF779056	viroverse:44503.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,27I,83L,148I,208G
MF779569	viroverse:44522.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779570	viroverse:44523.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779571	viroverse:44524.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779572	viroverse:44525.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,154K,199R,225S
MF779573	viroverse:44527.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,153IV,154K,178T,199R,225S
MF779574	viroverse:44528.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,80*,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779575	viroverse:44529.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,154K,199R,225S
MF780000	viroverse:44536.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF780001	viroverse:44537.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF780002	viroverse:44538.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF780003	viroverse:44539.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780004	viroverse:44540.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF780005	viroverse:44541.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF780006	viroverse:44542.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,83L,84HL,87Q,91V,98D,120S,180D,208G
MF780007	viroverse:44543.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,50T,71EG,83L,87Q,91V,98D,120S,180D,208G
MF780008	viroverse:44544.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780009	viroverse:44545.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF780010	viroverse:44546.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780011	viroverse:44547.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF780012	viroverse:44548.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780013	viroverse:44549.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,175EG,180D,208G
MF780014	viroverse:44550.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF780015	viroverse:44551.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,50T,53S,83L,87Q,91V,98D,120S,180D,208G
MF780016	viroverse:44552.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF780017	viroverse:44553.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779606	viroverse:44554.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779607	viroverse:44555.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779609	viroverse:44557.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779610	viroverse:44558.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779611	viroverse:44559.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,215MT,225S
MF779612	viroverse:44560.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779613	viroverse:44561.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,166N,199R,225S
MF779614	viroverse:44562.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779615	viroverse:44563.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779616	viroverse:44564.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779617	viroverse:44565.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779618	viroverse:44566.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779619	viroverse:44567.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779620	viroverse:44568.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779621	viroverse:44569.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF779622	viroverse:44570.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779923	viroverse:44571.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779924	viroverse:44572.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779925	viroverse:44573.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,18G,83L,87Q,91V,98D,120S,180D,208G
MF779926	viroverse:44574.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779927	viroverse:44575.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779576	viroverse:44577.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF780160	viroverse:44606.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780161	viroverse:44607.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780162	viroverse:44608.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780163	viroverse:44609.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780164	viroverse:44610.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780165	viroverse:44611.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780166	viroverse:44612.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780167	viroverse:44613.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780168	viroverse:44614.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780169	viroverse:44615.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780170	viroverse:44616.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780171	viroverse:44617.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,113D,116A,120S
MF780470	viroverse:44618.1	USA	Jun-1998		genomic DNA	plasma from subject F8	days-post-seroconversion:788; viral-load:1100;CD4-count:791; CD8-count:1226;subtype: B	1	231	6L,16T,27I,54L,79D,83T,148I,154K,178T,225S
MF780172	viroverse:44619.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780173	viroverse:44620.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780174	viroverse:44621.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780175	viroverse:44622.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780176	viroverse:44623.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780177	viroverse:44624.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,96V,110N,116A,120S
MF780178	viroverse:44625.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780179	viroverse:44626.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780180	viroverse:44627.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780181	viroverse:44628.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780182	viroverse:44629.1	USA	Nov-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:696; viral-load:26000;CD4-count:1064; CD8-count:1170;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF779484	viroverse:44650.1	USA	May-2004		genomic DNA	plasma from subject F4	days-post-seroconversion:627; viral-load:1000;CD4-count:453; CD8-count:256;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779485	viroverse:44651.1	USA	May-2004		genomic DNA	plasma from subject F4	days-post-seroconversion:627; viral-load:1000;CD4-count:453; CD8-count:256;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779486	viroverse:44652.1	USA	May-2004		genomic DNA	plasma from subject F4	days-post-seroconversion:627; viral-load:1000;CD4-count:453; CD8-count:256;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779487	viroverse:44653.1	USA	May-2004		genomic DNA	plasma from subject F4	days-post-seroconversion:627; viral-load:1000;CD4-count:453; CD8-count:256;subtype: B	1	231	6L,15L,27I,33N,36I,41T,59A,91V,120S,128D,148V,180D,199R,225S
MF778903	viroverse:44676.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,148I,154K
MF778904	viroverse:44677.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,83L
MF778905	viroverse:44678.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,148I
MF778906	viroverse:44679.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,148I
MF778907	viroverse:44680.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,120H,148I,154K,160S
MF778908	viroverse:44681.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,120H,148I,154K
MF778909	viroverse:44682.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,148I
MF778910	viroverse:44683.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,120H,148I,154K
MF778911	viroverse:44684.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,148I
MF778912	viroverse:44685.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,21NS,27I,83L,148I
MF778913	viroverse:44686.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,120H,148I,154K
MF778914	viroverse:44687.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,148I
MF778915	viroverse:44688.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,148I
MF778916	viroverse:44689.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,148I
MF778917	viroverse:44690.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,120H,148I,154K
MF778918	viroverse:44691.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,120H,148I,154K,160S
MF778919	viroverse:44692.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,148I
MF778920	viroverse:44693.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,148I
MF778921	viroverse:44694.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,83L
MF778922	viroverse:44695.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,27I,83L,148I
MF778923	viroverse:44696.1	USA	Apr-2001		genomic DNA	plasma from subject F1	days-post-seroconversion:1934; viral-load:1100;subtype: B	1	231	6L,83L,193NS
MF780041	viroverse:44744.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G,229K
MF780042	viroverse:44745.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780043	viroverse:44746.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780044	viroverse:44747.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780045	viroverse:44748.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780046	viroverse:44749.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,50T,69I,83L,87Q,91V,98D,120S,180D,192HQ,208G,229K
MF780047	viroverse:44750.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780049	viroverse:44752.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780050	viroverse:44753.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780051	viroverse:44754.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G,229K
MF780052	viroverse:44755.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G,229K
MF780053	viroverse:44756.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780054	viroverse:44757.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780055	viroverse:44758.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14K,50T,83L,87Q,91V,98D,120S,180D,208G
MF780056	viroverse:44759.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G,229K
MF780057	viroverse:44760.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780058	viroverse:44761.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G,230I
MF780059	viroverse:44762.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780060	viroverse:44763.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,50S,83L,87Q,91V,98D,120S,180D,208G
MF780061	viroverse:44764.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780203	viroverse:44765.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S
MF780204	viroverse:44766.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S
MF780205	viroverse:44767.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S
MF780206	viroverse:44768.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S
MF780207	viroverse:44769.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S
MF780208	viroverse:44770.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S
MF780209	viroverse:44771.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780210	viroverse:44772.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S
MF780211	viroverse:44773.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S
MF780212	viroverse:44774.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T
MF780213	viroverse:44775.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,106R,116A,120S
MF780214	viroverse:44776.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T
MF780215	viroverse:44777.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S
MF780216	viroverse:44778.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S
MF780217	viroverse:44779.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T
MF780218	viroverse:44780.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,96I,116A,120S
MF780219	viroverse:44781.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S
MF780220	viroverse:44782.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780221	viroverse:44783.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T
MF780222	viroverse:44784.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S
MF780223	viroverse:44785.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S
MF780224	viroverse:44786.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T
MF780225	viroverse:44787.1	USA	Oct-2004		genomic DNA	plasma from subject F7	days-post-seroconversion:1404; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S
MF778784	viroverse:44793.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF778785	viroverse:44794.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF778786	viroverse:44795.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF778787	viroverse:44796.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,25EK,44A,83L,110N,120H
MF778788	viroverse:44797.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF778789	viroverse:44798.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF778790	viroverse:44799.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF779928	viroverse:44800.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779929	viroverse:44801.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779930	viroverse:44802.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779931	viroverse:44803.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779932	viroverse:44804.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779933	viroverse:44805.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779577	viroverse:44813.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,154K,178T,199R,225S
MF780062	viroverse:44816.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780063	viroverse:44817.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF780064	viroverse:44818.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780065	viroverse:44819.1	USA	Dec-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3751; viral-load:7377;CD4-count:239; CD8-count:279;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G,229K
MF778791	viroverse:44831.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF778792	viroverse:44832.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF778793	viroverse:44833.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14S,44A,83L,110N,120H
MF778794	viroverse:44834.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF778795	viroverse:44835.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF778796	viroverse:44836.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF778797	viroverse:44837.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF778798	viroverse:44838.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF778799	viroverse:44839.1	USA	Mar-1996		genomic DNA	plasma from subject F1	days-post-seroconversion:74; viral-load:14000;CD4-count:700; CD8-count:665;subtype: B	1	231	6L,14P,44A,83L,110N,120H
MF779495	viroverse:44852.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779496	viroverse:44853.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779497	viroverse:44855.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779498	viroverse:44857.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779499	viroverse:44861.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779500	viroverse:44862.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF780139	viroverse:44884.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780140	viroverse:44885.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780141	viroverse:44886.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780142	viroverse:44887.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780143	viroverse:44888.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780144	viroverse:44889.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,27I,50H,91V,110N,116A,120S
MF780145	viroverse:44890.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,27I,50H,91V,110N,116A,120S
MF780146	viroverse:44891.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,27I,50H,91V,110N,116A,120S
MF780147	viroverse:44892.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780148	viroverse:44893.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF779009	viroverse:44913.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V,153V,183G,208G
MF779010	viroverse:44914.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,83L,148V,183G,208G
MF779011	viroverse:44915.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V,183G,208G
MF779012	viroverse:44916.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,134IV,148V,208G
MF779013	viroverse:44917.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V
MF780149	viroverse:44918.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780150	viroverse:44919.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780151	viroverse:44920.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,27I,50H,91V,110N,116A,120S
MF780152	viroverse:44921.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780153	viroverse:44922.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780154	viroverse:44923.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780155	viroverse:44924.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780156	viroverse:44925.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S,199EK
MF780157	viroverse:44926.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF780158	viroverse:44927.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,27I,50H,91V,110N,116A,120S
MF780159	viroverse:44928.1	USA	May-2002		genomic DNA	plasma from subject F7	days-post-seroconversion:530; viral-load:2600;CD4-count:1220; CD8-count:1045;subtype: B	1	231	6S,50H,91V,110N,116A,120S
MF779623	viroverse:44929.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779624	viroverse:44930.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,58ST,91V,120S,128D,148V,154K,178T,183R,199R,225S
MF779625	viroverse:44931.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779626	viroverse:44932.1	USA	Apr-2010		genomic DNA	plasma from subject F4	days-post-seroconversion:2788; viral-load:;CD4-count:193; CD8-count:304;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,199R,225S
MF778944	viroverse:44947.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,27I,83L,148V,192R
MF778945	viroverse:44948.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,83L,180D
MF778946	viroverse:44949.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,27I,83L,148V
MF778947	viroverse:44950.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,27I,83L,148V,178T
MF778948	viroverse:44951.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,27I,83L,148I
MF778949	viroverse:44952.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,27I,83L,148I
MF778950	viroverse:44953.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,11I,27I,83L,148I
MF778951	viroverse:44954.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,27I,83L,148I
MF778952	viroverse:44955.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,27I,83L,148V,183S
MF778954	viroverse:44957.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,83L,180D
MF778955	viroverse:44958.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,27I,83L,148V,178T,206R
MF778956	viroverse:44959.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,27I,83L,148V,178T
MF778957	viroverse:44960.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,27I,83L,148I
MF778958	viroverse:44961.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,27I,83L,148V
MF778959	viroverse:44962.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,27I,83L,148I
MF779014	viroverse:44963.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V
MF779015	viroverse:44964.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V,178T
MF779016	viroverse:44965.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V,178T
MF779017	viroverse:44966.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V,183S
MF779018	viroverse:44967.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,83L,148V,183G,208G
MF779019	viroverse:44968.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,13QR,83L,148V,183G,208G
MF779020	viroverse:44969.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,83L,148V,183G,208G
MF779021	viroverse:44970.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V,183S
MF779022	viroverse:44971.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,83L,148V,183G,191I,208G
MF779023	viroverse:44972.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V
MF779024	viroverse:44973.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V,183S
MF779025	viroverse:44974.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V,178T
MF779026	viroverse:44975.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,83L,148V,183G,208G
MF779027	viroverse:44977.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,83L,148V,183G,208G
MF779028	viroverse:44978.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V,183S
MF779029	viroverse:44979.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V,183S
MF779030	viroverse:44980.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,83L,148V,183G,208G
MF778986	viroverse:45017.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,27I,83L,148V,183S
MF778987	viroverse:45018.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,27I,83L,148V,183S
MF778988	viroverse:45019.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,83L,148V,183G
MF778989	viroverse:45020.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,27I,83L,148V
MF778990	viroverse:45021.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,83L,148V,183G,199X
MF778991	viroverse:45022.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,27I,83L,148V,178T,183S
MF778992	viroverse:45023.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,27I,83L,148V
MF778993	viroverse:45024.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,27I,83L,148V,183S
MF778994	viroverse:45025.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,27I,83L,148I,208G
MF778995	viroverse:45026.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,27I,83L,148I
MF778996	viroverse:45027.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,83L,148V,183G
MF778997	viroverse:45028.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,83L,148V,183G
MF778998	viroverse:45029.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,27I,83L,148V
MF778999	viroverse:45030.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,27I,83L,148V,180D
MF779000	viroverse:45031.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,83L,148V,183G
MF779501	viroverse:45033.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779502	viroverse:45034.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,136P,143G,148V,180D,199R,225S
MF779503	viroverse:45035.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779504	viroverse:45036.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779505	viroverse:45037.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779506	viroverse:45038.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779507	viroverse:45039.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779508	viroverse:45040.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779509	viroverse:45041.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779510	viroverse:45042.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779511	viroverse:45043.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,105AV,120S,128D,148V,180D,199R,225S
MF779512	viroverse:45044.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,11AV,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779002	viroverse:45045.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,27I,32CFSY,83L,148V,183S
MF779003	viroverse:45046.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,27I,83L,148V
MF779004	viroverse:45047.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,27I,83L,148V
MF779005	viroverse:45048.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,27I,83L,148V,183G
MF779006	viroverse:45049.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,27I,83L,148V,178T,213X
MF779007	viroverse:45050.1	USA	Apr-2005		genomic DNA	plasma from subject F1	days-post-seroconversion:3389; viral-load:8600;CD4-count:127; CD8-count:478;subtype: B	1	231	6L,83L,148V,183G
MF779031	viroverse:45066.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V,183S
MF779032	viroverse:45067.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,83L,148V,183G,208G
MF779033	viroverse:45068.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V,183S
MF779034	viroverse:45069.1	USA	Apr-2006		genomic DNA	plasma from subject F1	days-post-seroconversion:3754; viral-load:17000;CD4-count:295; CD8-count:816;subtype: B	1	231	6L,27I,83L,148V,183S,208G
MF779462	viroverse:45084.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,155R,180D,188I,199R,225S
MF779463	viroverse:45085.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779464	viroverse:45087.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779465	viroverse:45089.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779466	viroverse:45090.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779467	viroverse:45091.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779468	viroverse:45092.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779469	viroverse:45093.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779470	viroverse:45094.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779471	viroverse:45095.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF778960	viroverse:45098.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,27I,83L,148V,178T
MF778961	viroverse:45099.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,27I,83L,148V
MF778962	viroverse:45100.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,83L,148I,180D
MF779934	viroverse:45103.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779935	viroverse:45104.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,201T,208G
MF780340	viroverse:45106.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF779578	viroverse:45108.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779579	viroverse:45109.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,87Q,91V,120S,128D,148V,154K,178T,199R,225S
MF779580	viroverse:45110.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779581	viroverse:45111.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779582	viroverse:45112.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,199R,225S
MF779583	viroverse:45113.1	USA	Apr-2008		genomic DNA	plasma from subject F4	days-post-seroconversion:2055; viral-load:7800;CD4-count:219; CD8-count:316;subtype: B	1	231	6L,15L,27I,33N,36I,41T,83M,91V,120S,128D,148V,154K,178T,180D,199R,225S
MF780341	viroverse:45114.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF779936	viroverse:45115.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779937	viroverse:45117.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779938	viroverse:45118.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779939	viroverse:45119.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779940	viroverse:45120.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,10T,14N,83L,87Q,91V,98D,120S,180D,208G
MF780342	viroverse:45125.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,83I,91V,116A,120S,216S
MF780343	viroverse:45126.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780344	viroverse:45127.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780345	viroverse:45128.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780346	viroverse:45129.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,83I,91V,116A,120S,178T,216S
MF780347	viroverse:45130.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780348	viroverse:45131.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780349	viroverse:45132.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S
MF780350	viroverse:45133.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780351	viroverse:45155.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780352	viroverse:45156.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780353	viroverse:45157.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780354	viroverse:45158.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,61E,91V,116A,120S,124T,178T,216S
MF780355	viroverse:45164.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780356	viroverse:45165.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780357	viroverse:45166.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780358	viroverse:45167.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780359	viroverse:45168.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780360	viroverse:45169.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780361	viroverse:45170.1	USA	Oct-2010		genomic DNA	plasma from subject F7	days-post-seroconversion:3601; viral-load:7592;CD4-count:688; CD8-count:931;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF779947	viroverse:45171.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779948	viroverse:45172.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779949	viroverse:45176.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779950	viroverse:45177.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779951	viroverse:45178.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779952	viroverse:45179.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779953	viroverse:45180.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779954	viroverse:45181.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779955	viroverse:45186.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,50T,71K,83L,87Q,91V,98D,120S,180D,208G
MF779956	viroverse:45187.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779957	viroverse:45190.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,176QR,180D,208G
MF778963	viroverse:45191.1	USA	Apr-2003		genomic DNA	plasma from subject F1	days-post-seroconversion:2663; viral-load:80;CD4-count:182; CD8-count:474;subtype: B	1	231	6L,27I,81DG,83L,148V,178T
MF780247	viroverse:45201.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,183S
MF780248	viroverse:45203.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780249	viroverse:45206.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,72AT,91V,116A,120S,166DG,216S
MF780250	viroverse:45207.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780251	viroverse:45208.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780252	viroverse:45209.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780253	viroverse:45210.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780254	viroverse:45211.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,180D
MF780255	viroverse:45212.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780256	viroverse:45213.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780257	viroverse:45214.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780258	viroverse:45215.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780259	viroverse:45216.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780260	viroverse:45218.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780261	viroverse:45223.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780262	viroverse:45226.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,197N,216S
MF780263	viroverse:45228.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780264	viroverse:45229.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780265	viroverse:45231.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780266	viroverse:45238.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780267	viroverse:45240.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,21S,50H,91V,116A,120S,216S
MF780268	viroverse:45241.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780269	viroverse:45243.1	USA	Oct-2006		genomic DNA	plasma from subject F7	days-post-seroconversion:2132; viral-load:8100;CD4-count:599; CD8-count:699;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780362	viroverse:45257.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780363	viroverse:45258.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780364	viroverse:45259.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780365	viroverse:45260.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,31AV,50H,91V,116A,120S,178T,216S
MF780366	viroverse:45261.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780367	viroverse:45262.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780368	viroverse:45263.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780369	viroverse:45264.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780370	viroverse:45265.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780371	viroverse:45266.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780372	viroverse:45267.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780373	viroverse:45268.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,11I,50H,91V,116A,120S,178T,183S
MF780374	viroverse:45269.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780375	viroverse:45270.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780376	viroverse:45271.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,87Q,91V,116A,120S,216S
MF780377	viroverse:45272.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,83I,91V,116A,120S,178T,216S
MF780378	viroverse:45273.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780379	viroverse:45274.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780380	viroverse:45275.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780381	viroverse:45276.1	USA	Oct-2011		genomic DNA	plasma from subject F7	days-post-seroconversion:3960; viral-load:;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780020	viroverse:45297.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780021	viroverse:45298.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780022	viroverse:45299.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780023	viroverse:45300.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G,229K
MF780024	viroverse:45301.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,25KQ,83L,91V,98D,120S,180D,208G
MF780025	viroverse:45302.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780026	viroverse:45303.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780027	viroverse:45304.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780028	viroverse:45305.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780029	viroverse:45306.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780030	viroverse:45307.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780031	viroverse:45308.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780032	viroverse:45309.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780033	viroverse:45310.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780034	viroverse:45311.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780035	viroverse:45312.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780036	viroverse:45313.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780037	viroverse:45314.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G,229K
MF780038	viroverse:45315.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G,229K
MF780039	viroverse:45316.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,83L,91V,98D,120S,180D,208G
MF780040	viroverse:45317.1	USA	Jun-2009		genomic DNA	plasma from subject F6	days-post-seroconversion:3581; viral-load:1581;CD4-count:663; CD8-count:782;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779941	viroverse:45343.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779942	viroverse:45345.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779943	viroverse:45347.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779944	viroverse:45348.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779945	viroverse:45349.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779946	viroverse:45350.1	USA	Nov-2004		genomic DNA	plasma from subject F6	days-post-seroconversion:1901; viral-load:2900;CD4-count:409; CD8-count:302;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779958	viroverse:45354.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779959	viroverse:45355.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779960	viroverse:45356.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779961	viroverse:45357.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779783	viroverse:45360.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,181X,182X,199R,216S
MF779784	viroverse:45361.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R
MF779785	viroverse:45362.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R,216S
MF779786	viroverse:45363.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R
MF779787	viroverse:45364.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779788	viroverse:45365.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R
MF779789	viroverse:45366.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R
MF779790	viroverse:45367.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R
MF779791	viroverse:45368.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6M,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779792	viroverse:45369.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6M,14P,16A,41A,81DG,83I,116A,132K,136I,141V,154K,178T,199R
MF779962	viroverse:45370.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779963	viroverse:45371.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779964	viroverse:45372.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779965	viroverse:45373.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779966	viroverse:45374.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779967	viroverse:45375.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779968	viroverse:45376.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779969	viroverse:45377.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779970	viroverse:45378.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779971	viroverse:45379.1	USA	Nov-2005		genomic DNA	plasma from subject F6	days-post-seroconversion:2266; viral-load:9400;CD4-count:585; CD8-count:519;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF779793	viroverse:45391.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779794	viroverse:45392.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R,216S
MF779795	viroverse:45393.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779796	viroverse:45394.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R
MF779797	viroverse:45395.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R
MF779798	viroverse:45396.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779799	viroverse:45397.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6M,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R
MF779800	viroverse:45398.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779801	viroverse:45399.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,212K,216S
MF779802	viroverse:45400.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779803	viroverse:45401.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R
MF779804	viroverse:45403.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6M,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R
MF780560	viroverse:45405.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780562	viroverse:45407.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,27I,41T,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780563	viroverse:45408.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780564	viroverse:45409.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,16T,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780565	viroverse:45410.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780566	viroverse:45411.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780567	viroverse:45412.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780568	viroverse:45413.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,27I,41T,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780569	viroverse:45414.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780570	viroverse:45415.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780571	viroverse:45416.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780572	viroverse:45417.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780573	viroverse:45418.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780574	viroverse:45419.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780575	viroverse:45420.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780576	viroverse:45421.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,209V,225S
MF780577	viroverse:45422.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780018	viroverse:45451.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,208G
MF780019	viroverse:45454.1	USA	Nov-2007		genomic DNA	plasma from subject F6	days-post-seroconversion:2982; viral-load:4400;CD4-count:653; CD8-count:638;subtype: B	1	231	6L,14N,50T,83L,87Q,91V,98D,120S,180D,191I,208G
MF779057	viroverse:45465.1	USA	Apr-2007		genomic DNA	plasma from subject F1	days-post-seroconversion:4118; viral-load:17000;CD4-count:167; CD8-count:590;subtype: B	1	231	6L,27I,83L,148V,208G
MF779826	viroverse:45466.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779827	viroverse:45467.1	USA	Apr-2003		genomic DNA	plasma from subject F5	days-post-seroconversion:2276; viral-load:360000;CD4-count:3; CD8-count:154;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779805	viroverse:45511.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136M,141V,154K,178T,199R,216S
MF779806	viroverse:45512.1	USA	Apr-2002		genomic DNA	plasma from subject F5	days-post-seroconversion:1922; viral-load:250000;subtype: B	1	231	6L,14P,16A,41A,83I,116A,132K,136I,141V,154K,178T,199R
MF780270	viroverse:45519.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,178T,183S,216S
MF780271	viroverse:45520.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780272	viroverse:45521.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,178T,183S,216S
MF780273	viroverse:45522.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780274	viroverse:45523.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780275	viroverse:45524.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780276	viroverse:45525.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780277	viroverse:45526.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780278	viroverse:45527.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780279	viroverse:45528.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780280	viroverse:45529.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780281	viroverse:45530.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780282	viroverse:45531.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,216S,220AEGV
MF780283	viroverse:45532.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780284	viroverse:45533.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780285	viroverse:45534.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780286	viroverse:45535.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780287	viroverse:45536.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780288	viroverse:45537.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780289	viroverse:45538.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780290	viroverse:45539.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,216S
MF780291	viroverse:45540.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780292	viroverse:45541.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780293	viroverse:45542.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780294	viroverse:45543.1	USA	Oct-2007		genomic DNA	plasma from subject F7	days-post-seroconversion:2496; viral-load:3400;CD4-count:1165; CD8-count:1327;subtype: B	1	231	6S,50H,91V,116A,120S,178T,216S
MF780578	viroverse:45544.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780579	viroverse:45545.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780580	viroverse:45546.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780581	viroverse:45547.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	14S,15L,27I,54L,79D,83T,87Q,120S,148V,154K,178T,225S
MF780582	viroverse:45548.1	USA	Mar-2006		genomic DNA	plasma from subject F8	days-post-seroconversion:3616; viral-load:25000;CD4-count:27; CD8-count:995;subtype: B	1	231	6L,14S,15L,27I,54L,72AT,79D,83T,87Q,120S,148V,154K,178T,225S
MF779407	viroverse:45551.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779408	viroverse:45552.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779409	viroverse:45553.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779410	viroverse:45554.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779411	viroverse:45555.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779412	viroverse:45556.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779413	viroverse:45557.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779414	viroverse:45558.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779415	viroverse:45559.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779416	viroverse:45560.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779417	viroverse:45561.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779418	viroverse:45562.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779419	viroverse:45563.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779420	viroverse:45564.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779421	viroverse:45565.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779422	viroverse:45566.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L,139NS
MF779423	viroverse:45567.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779424	viroverse:45568.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779425	viroverse:45569.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779426	viroverse:45570.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86AV
MF779427	viroverse:45571.1	USA	Apr-2007		genomic DNA	plasma from subject F3	days-post-seroconversion:1734; viral-load:19000;CD4-count:269; CD8-count:1308;subtype: B	1	231	6S,11T,15L,50H,71D,83L,86I
MF779670	viroverse:45603.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779671	viroverse:45604.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779672	viroverse:45609.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6L,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779673	viroverse:45610.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779674	viroverse:45611.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779675	viroverse:45612.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779081	viroverse:45614.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779082	viroverse:45615.2	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779083	viroverse:45616.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779084	viroverse:45617.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,26X,27~,28~,29X,83L,91V,96L,116A,120A,123A,148V,180D
MF779085	viroverse:45618.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779086	viroverse:45619.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779087	viroverse:45620.2	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779088	viroverse:45621.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779089	viroverse:45622.2	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779090	viroverse:45623.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779091	viroverse:45625.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779092	viroverse:45626.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779900	viroverse:45677.1	USA	Nov-2002		genomic DNA	plasma from subject F6	days-post-seroconversion:1160; viral-load:9400;CD4-count:630; CD8-count:389;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF778964	viroverse:45678.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148V,183S
MF778965	viroverse:45679.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148I
MF778966	viroverse:45680.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,21DN,27I,83L,148V,183S
MF778967	viroverse:45681.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148I
MF778968	viroverse:45682.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148V,183S
MF778969	viroverse:45683.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148I,161FS
MF778970	viroverse:45684.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148V,178T
MF778971	viroverse:45685.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148I
MF778972	viroverse:45686.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148V,183S
MF779093	viroverse:45687.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779094	viroverse:45688.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779095	viroverse:45689.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779096	viroverse:45690.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779097	viroverse:45691.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,14AV,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779098	viroverse:45692.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779099	viroverse:45693.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,128K,148V,180D
MF779100	viroverse:45694.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D,227R
MF779101	viroverse:45695.3	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779102	viroverse:45696.2	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779103	viroverse:45697.1	USA	Jan-1999		genomic DNA	plasma from subject F2	days-post-seroconversion:92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779264	viroverse:45698.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779265	viroverse:45699.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779266	viroverse:45700.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779267	viroverse:45701.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779268	viroverse:45702.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779269	viroverse:45703.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L,202S
MF779270	viroverse:45704.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779271	viroverse:45705.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779272	viroverse:45706.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779273	viroverse:45707.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779274	viroverse:45708.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779275	viroverse:45709.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779276	viroverse:45710.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779277	viroverse:45711.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779278	viroverse:45712.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779279	viroverse:45713.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779280	viroverse:45714.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779281	viroverse:45715.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779282	viroverse:45716.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779283	viroverse:45717.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,25KR,50H,71D,83L
MF779284	viroverse:45718.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779285	viroverse:45719.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779286	viroverse:45720.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF779287	viroverse:45721.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L,103DG
MF778973	viroverse:45725.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148I
MF778974	viroverse:45726.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148V
MF778975	viroverse:45727.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148I
MF778976	viroverse:45728.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148V
MF778977	viroverse:45729.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148V,180D,230I
MF778978	viroverse:45730.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148I,180D
MF779451	viroverse:45735.1	USA	Nov-2002		genomic DNA	plasma from subject F4	days-post-seroconversion:81; viral-load:80;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779452	viroverse:45736.1	USA	Nov-2002		genomic DNA	plasma from subject F4	days-post-seroconversion:81; viral-load:80;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779453	viroverse:45737.1	USA	Nov-2002		genomic DNA	plasma from subject F4	days-post-seroconversion:81; viral-load:80;subtype: B	1	231	6L,15L,27I,33N,36I,41T,84HR,91V,120S,128D,148V,180D,199R,225S
MF779454	viroverse:45738.1	USA	Nov-2002		genomic DNA	plasma from subject F4	days-post-seroconversion:81; viral-load:80;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779455	viroverse:45739.1	USA	Nov-2002		genomic DNA	plasma from subject F4	days-post-seroconversion:81; viral-load:80;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF780395	viroverse:45740.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF779288	viroverse:45741.1	USA	Oct-2002		genomic DNA	plasma from subject F3	days-post-seroconversion:94; viral-load:;subtype: B	1	231	6S,11T,15L,50H,71D,83L
MF778979	viroverse:45742.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148I
MF778980	viroverse:45743.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148V,178T
MF778981	viroverse:45744.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148I
MF778982	viroverse:45745.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148I
MF778983	viroverse:45746.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148I
MF778984	viroverse:45747.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148I
MF778985	viroverse:45748.1	USA	Apr-2004		genomic DNA	plasma from subject F1	days-post-seroconversion:3025; viral-load:10000;CD4-count:173; CD8-count:672;subtype: B	1	231	6L,27I,83L,148V,178T
MF779472	viroverse:47305.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,215MV,225S
MF779461	viroverse:47345.1	USA	May-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:261; viral-load:80;CD4-count:577; CD8-count:301;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779488	viroverse:47400.1	USA	May-2004		genomic DNA	plasma from subject F4	days-post-seroconversion:627; viral-load:1000;CD4-count:453; CD8-count:256;subtype: B	1	231	6L,18G,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779489	viroverse:47401.1	USA	May-2004		genomic DNA	plasma from subject F4	days-post-seroconversion:627; viral-load:1000;CD4-count:453; CD8-count:256;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779490	viroverse:47402.1	USA	May-2004		genomic DNA	plasma from subject F4	days-post-seroconversion:627; viral-load:1000;CD4-count:453; CD8-count:256;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779491	viroverse:47404.1	USA	May-2004		genomic DNA	plasma from subject F4	days-post-seroconversion:627; viral-load:1000;CD4-count:453; CD8-count:256;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779492	viroverse:47405.1	USA	May-2004		genomic DNA	plasma from subject F4	days-post-seroconversion:627; viral-load:1000;CD4-count:453; CD8-count:256;subtype: B	1	231	6L,15L,27I,33N,36I,39T,41T,91V,120S,128D,148V,180D,199R,225S
MF779493	viroverse:47406.1	USA	May-2004		genomic DNA	plasma from subject F4	days-post-seroconversion:627; viral-load:1000;CD4-count:453; CD8-count:256;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779835	viroverse:47470.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779836	viroverse:47471.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779837	viroverse:47472.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779838	viroverse:47473.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779839	viroverse:47474.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779840	viroverse:47475.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779841	viroverse:47476.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779842	viroverse:47477.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779843	viroverse:47478.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779844	viroverse:47479.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779845	viroverse:47480.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779846	viroverse:47481.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779847	viroverse:47482.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779848	viroverse:47483.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779849	viroverse:47484.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779850	viroverse:47485.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779851	viroverse:47486.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779852	viroverse:47487.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779853	viroverse:47488.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779854	viroverse:47489.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,180D,208G
MF779855	viroverse:47490.1	USA	Sep-2001		genomic DNA	plasma from subject F6	days-post-seroconversion:739; viral-load:1100;CD4-count:1103; CD8-count:572;subtype: B	1	231	6L,14N,83L,87Q,91V,98D,120S,139HN,180D,208G
MF780396	viroverse:47518.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780397	viroverse:47520.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780398	viroverse:47521.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780399	viroverse:47522.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF779473	viroverse:47523.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF780400	viroverse:47525.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780401	viroverse:47526.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780402	viroverse:47528.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,96I,148I,154K,178T,210S,225S
MF780403	viroverse:47530.1	USA	Jul-1996		genomic DNA	plasma from subject F8	days-post-seroconversion:89; viral-load:5800;CD4-count:795; CD8-count:1526;subtype: B	1	231	6L,27I,54L,79D,83M,148I,154K,178T,210S,225S
MF779474	viroverse:47531.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779475	viroverse:47532.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779476	viroverse:47533.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779477	viroverse:47534.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779478	viroverse:47535.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779479	viroverse:47536.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779480	viroverse:47537.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779481	viroverse:47545.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779482	viroverse:47546.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779483	viroverse:47547.1	USA	Nov-2003		genomic DNA	plasma from subject F4	days-post-seroconversion:444; viral-load:1500;CD4-count:761; CD8-count:507;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779456	viroverse:47551.1	USA	Nov-2002		genomic DNA	plasma from subject F4	days-post-seroconversion:81; viral-load:80;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779457	viroverse:47552.1	USA	Nov-2002		genomic DNA	plasma from subject F4	days-post-seroconversion:81; viral-load:80;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779458	viroverse:47553.1	USA	Nov-2002		genomic DNA	plasma from subject F4	days-post-seroconversion:81; viral-load:80;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779676	viroverse:47568.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779677	viroverse:47570.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6L,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779678	viroverse:47573.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779679	viroverse:47575.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779680	viroverse:47578.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779681	viroverse:47579.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779682	viroverse:47580.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,90S,116T,120S,126I,132K,136M,141V,154K,178T
MF779683	viroverse:47581.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779684	viroverse:47582.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779685	viroverse:47583.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6L,9R,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779686	viroverse:47584.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779687	viroverse:47585.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6L,14P,16A,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T,213EK
MF779688	viroverse:47602.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779689	viroverse:47603.1	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T
MF779058	viroverse:47614.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,106E,116A,120A,123A,148V,180D
MF779059	viroverse:47615.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779060	viroverse:47618.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779061	viroverse:47620.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779062	viroverse:47625.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779063	viroverse:47626.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779064	viroverse:47627.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779065	viroverse:47628.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779066	viroverse:47629.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779067	viroverse:47630.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779068	viroverse:47631.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779069	viroverse:47632.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779070	viroverse:47635.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779071	viroverse:47636.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779072	viroverse:47637.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D,182KR
MF779073	viroverse:47638.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779074	viroverse:47640.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779075	viroverse:47641.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,177V,180D,217T
MF779076	viroverse:47642.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779077	viroverse:47645.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779078	viroverse:47646.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779079	viroverse:47648.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779080	viroverse:47652.1	USA	Jul-1998		genomic DNA	plasma from subject F2	days-post-seroconversion:-92; viral-load:;subtype: B	1	231	6L,27I,83L,91V,96L,116A,120A,123A,148V,180D
MF779513	viroverse:47671.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779514	viroverse:47672.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779515	viroverse:47673.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779516	viroverse:47674.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779517	viroverse:47675.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779518	viroverse:47676.1	USA	May-2005		genomic DNA	plasma from subject F4	days-post-seroconversion:990; viral-load:8700;CD4-count:384; CD8-count:292;subtype: B	1	231	6L,15L,27I,33N,36I,41T,91V,120S,128D,148V,180D,199R,225S
MF779690	viroverse:47874.2	USA	Oct-1997		genomic DNA	plasma from subject F5	days-post-seroconversion:281; viral-load:400;CD4-count:818; CD8-count:562;subtype: B	1	231	6M,14P,16T,41A,83M,116T,120S,126I,132K,136M,141V,154K,178T